PulmoSIM Therapeutics

PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life. PulmoSIM is developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. PulmoSIM's approach can modulate multiple biological pathways with a single drug, reducing the need for combination therapies. By repurposing FDA-approved drugs, PulmoSIM aims to effectively target the underlying biology of PAH and IPF.